Abandoning testing for asymptomatic microscopic haematuria in Sweden – a long-term follow-up
DOI:
https://doi.org/10.2340/sju.v58.11142Keywords:
epidemiology, public health, hematuria, urinary bladder cancer, health care costsAbstract
Objectives: To test the hypothesis that the Swedish national policy of abandoning testing for asymptomatic microscopic haematuria (AMH) introduced in 1999 did not adversely affect the prognosis of patients with urinary bladder cancer. Specific aims were to investigate possible effects on (1) Diagnostic delay as represented by stage distribution at diagnosis, (2) Survival and mortality trends, also in comparison to other countries and (3) National health care costs.
Material and methods: The design was an observational study using open sources on patients included in the Swedish National Bladder Cancer Registry 1997–2016. Outcome measures were: Changes in initial tumour presentation during 5 years after the change and long-term relative survival and mortality in comparison to the other Nordic countries. Costs related to investigations were estimated based on the national price lists.
Results: The proportion of patients diagnosed with muscle-invasive bladder cancer decreased following the policy change. The long-term relative 5-year survival increased during the study period. Mortality has remained constant during the period. In comparison to the other Nordic countries, Sweden remains among those with the best outcome despite a more restrictive approach. Cost savings because of the policy change were estimated to be substantial.
Conclusions: Based on open-source registry data, the new restrictive policy was not found to adversely affect the survival of patients with urinary bladder cancer in Sweden. These observations argue against a major negative impact of abandoning further work-up for patients with AMH and may be of use for other countries when revising guidelines. The reduced number of patients undergoing investigation may allow for increased focus and be a relief both for caregivers and the health budget.
Downloads
References
Wallis CJD, Klaassen Z. Optimizing management of patients with microhematuria: gold down the drain? Can Urol Assoc J. 2019; 13:412–413. https://doi.org/10.5489/cuaj.6315 DOI: https://doi.org/10.5489/cuaj.6315
Rai BP, Luis Dominguez Escrig J, Vale L, et al. Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria. Eur Urol. 2022; 82:182–192. https://doi.org/10.1016/j.eururo.2022.03.027 DOI: https://doi.org/10.1016/j.eururo.2022.03.027
Malmström PU. Time to abandon testing for microscopic haematuria in adults? BMJ. 2003; 326:813–815. https://doi.org/10.1136/bmj.326.7393.813 DOI: https://doi.org/10.1136/bmj.326.7393.813
Kotb AF, Attia D. High-grade microscopic hematuria in adult men can predict urothelial malignancy. Can Urol Assoc J. 2014; 8:7–8. https://doi.org/10.5489/cuaj.1746 DOI: https://doi.org/10.5489/cuaj.1746
Linder BJ, Bass EJ, Mostafid H, Boorjian SA. Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 2018; 121:176–183. https://doi.org/10.1111/bju.14016 DOI: https://doi.org/10.1111/bju.14016
Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU guideline. J Urol. 2020; 204:778–786. https://doi.org/10.1097/JU.0000000000001297 DOI: https://doi.org/10.1097/JU.0000000000001297
Liedberg F, Gerdtham U, Gralén K, et al. Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective: results from a prospective intervention study. Br J Cancer. 2016; 115:770–775. https://doi.org/10.1038/bjc.2016.265 DOI: https://doi.org/10.1038/bjc.2016.265
Boman H, Hedelin H, Holmäng S. The results of routine evaluation of adult patients with haematuria analysed according to referral form information with 2year follow-up. Scand J Urol Nephrol. 2001; 35:497–501. https://doi.org/10.1080/003655901753367613 DOI: https://doi.org/10.1080/003655901753367613
Matulewicz RS, DeLancey JO, Pavey E, et al. Dipstick urinalysis as a test for microhematuria and occult bladder cancer. Bladder Cancer. 2017; 3:45–49. https://doi.org/10.3233/BLC-160068 DOI: https://doi.org/10.3233/BLC-160068
Malmström PU, Skaaheim Haug E, Boström PJ, et al. Progress towards a Nordic standard for the investigation of hematuria: 2019. Scand J Urol. 2019; 53: 1–6. https://doi.org/10.1080/21681805.2018.1555187 DOI: https://doi.org/10.1080/21681805.2018.1555187
Halpern JA, Chughtai B, Ghomrawi H. Cost-effectiveness of common diagnostic approaches for evaluation of asymptomatic micro-scopic hematuria. JAMA Int Med. 2017; 177:800–807. https://doi.org/10.1001/jamainternmed.2017.0739 DOI: https://doi.org/10.1001/jamainternmed.2017.0739
Assmus MA, Beyer DB, Hanks J, et al. Quality and cost assessment of Canadian Urological Association microscopic hematuria guide-lines in clinical practice: turning urine into gold. Can Urol Assoc J. 2019; 13:406–411. https://doi.org/10.5489/cuaj.5809 DOI: https://doi.org/10.5489/cuaj.5809
Waisbrod S, Natsos A, Wettstein MS, et al. Assessment of diagnostic yield of cystoscopy and computed tomographic urography for urinary tract cancers in patients evaluated for microhematuria: a systematic review and meta-analysis. JAMA Netw Open. 2021; 4:e218409. https://doi.org/10.1001/jamanetworkopen.2021.8409 DOI: https://doi.org/10.1001/jamanetworkopen.2021.8409
GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017; 389:1885–1906. DOI: https://doi.org/10.1016/S0140-6736(17)30819-X
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Per-Uno Malmström, Truls
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
